Mycosol, Inc.

Wit IP Corporation

Acmi Corporation

Angiosonics Inc.

Richard Barry Klein

John Joseph Partridge

Jeffrey Leaman Selph

Iulian Cioanta

John Reinhard

Jacob Lazarovitz

Uzi Eshel

Uri Rosenschein

John Popow

Phil Bell

Weng Lee

Jordan Dimitrakov

Pegylated pyridinium and thiazolium compounds and methods of their use in medicine, research, industry, agriculture and recreational activities are disclosed. The present invention also provides methods of controlling microbial growth and infection. Additionally, the present invention provides methods of controlling microbial infestations relating to industrial and agricultural uses. The present invention can also be used to control insects.

Pyridinium and thiazolium conjugates including polyethylene glycols and methods of using the same

Compounds of pyridinium salts and methods of their use in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, infectious conditions, as well as immune disorders are disclosed. The present invention also relates to methods of controlling fungi and/or bacteria.

Methods of treating inflammations and infections with pyridinium salts

The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.

Compounds and methods for controlling fungi, bacteria and insects

The present invention includes compounds of pyridinium salts and methods of their use for agricultural purposes. The present invention also relates to methods of controlling fungi and/or bacteria.

Methods for controlling fungi and bacteria

Methods, systems, and computer program products for providing thermal therapies or internal thermal massage therapy for treating prostatitis by expanding and contracting a treatment balloon with inflation media and currently applying heat to a portion of the prostatic urethra.

Methods for treating prostatitis

An indwelling catheter for insertion into a patient's urinary tract is provided that includes first and second tubular members that enable drainage of physiological fluids. An inflatable balloon is attached to the second tubular member. The first and second tubular members are interconnected by a connecting tube forming a gap between the first and second tubular members. The connecting tube is in fluid communication with the balloon to enable the balloon to be inflated via the connecting tube. When the balloon is anchored within the urinary bladder the second tubular member is located within the prostatic urethra with one end in close proximity to the sphincter and the other end protruding into the urinary bladder. The first tubular member is located within the penile urethra with one end in close proximity to the sphincter so that the connecting tube traverses the sphincter permitting voluntary control of the sphincter.

Urethral catheter and guide

Flexible treatment catheters are configured to be inserted into a body lumen or cavity to deliver heated fluid through at least one fluid lumen therein to thermally treat or ablate a targeted site in a biological subject. The flexible treatment catheters can include improved thermally insulated regions comprising a mixture formed of liquid elastomeric (such as a polyurethane) mixture (which transitions to a solid state) and miniaturized hollow plastic bodies positioned between the outer wall of the treatment catheter and the fluid lumen. The thermally insulated region is configured such that, measured ex vivo, the treatment catheter can present a maximum temperature of below about 45&deg; C. on the external surface of the outer wall of the treatment catheter when the treatment catheter circulates fluid having an inlet temperature of above or between about 60&deg;-62&deg; C. Alternatively or additionally, the treatment catheter can include an elongated insert positioned in a catheter fluid lumen to inhibit the closure of the lumen after exposure to fluids in the treatment catheter at temperatures sufficient to thermal ablate targeted tissue over a thermal ablation treatment period. The treatment catheter can include a urinary drainage lumen with an elongated insert frictionally engaged therewith, the drainage lumen and insert are configured to provide a fluid volume throughput through the drainage lumen of greater than about 20-25 ml/min during and after (for about 12-72 hours after) a thermal ablation session.

Treatment catheters with thermally insulated regions

A prostatic stent is configured as a unitary body, which is adapted to reside above the sphincter when in position in a subject and allow normal functioning of the sphincter. The stent includes and elongated and substantially narrow conduit, which extends through the sphincter and outside the body of the subject. The conduit is sized and constructed to allow normal operation of the sphincter. The stent also includes and upper and/or an intermediate inflatable portions and may include a second conduit for the introduction of medication to the stent.

Prostatic stent with localized tissue engaging anchoring means and methods for inhibiting obstruction of the prostatic urethra

Methods of treating the prostate include administering a thermal ablation therapy and inhibiting the obstruction or closure of the prostatic urethral opening by forming a biodegradable stent in situ in the subject such that the stent attaches to the walls of the prostatic urethra. A related method of treating BPH includes thermally treating or ablating localized tissue in the prostate with a treatment catheter and inserting flowable stent material via the treatment catheter into the prostate (either before, during, or after the thermal treatment), forming the flowable stent material so that it defines a stent that remains in position after removal of the treatment catheter to inhibit the closure of the urinary passage. Associated stents and catheters are included.

Methods for treating the prostate and inhibiting obstruction of the prostatic urethra using biodegradable stents

A control system for a probe, including a transmission member, comprises a power source for supplying a constant power to a transmission member and a transducer for coupling the constant power to the transmission member and for providing a mechanical output to the transmission member at a frequency. A frequency measuring device is also provided for constantly measuring the frequency of the mechanical output of the transducer. A current monitoring device for measuring current forwarded to the transducer which monitors the current while the frequency of said mechanical output is varied until it is determined at what frequency the current is at a maximum is also provided. A method for implementing this apparatus is also provided.

Growing community of inventors

Cary, NC, United States of America

Richard Barry Klein